They were both affected by advanced prostate cancer and developed LHON after introduction of enzalutamide, an antagonist of androgens’ receptor, in association with leuprolide, a gonadotropin-releasing hormone (GnRH) analogue, used in the context of Androgen deprivation therapy (ADT). The gene discussed is GNRH1; the disease is Leber hereditary optic neuropathy.